Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012
Imeglimin beneficial as add-on to metformin in T2DM
For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.

Pascale Fouqueray, M.D., of Poxel in Lyon, France, and colleagues conducted a 12-week, phase II, randomized, controlled study involving 156 patients with type 2 diabetes who were inadequately controlled on metformin alone to assess the efficacy and safety of imeglimin as add-on therapy. Patients received a stable dose of metformin (1,500 to 2,000 mg/day) plus imeglimin (1,500 mg twice daily) or placebo.

After 12 weeks, the researchers found that the placebo-subtracted decrease in hemoglobin A1c was a significant −0.44 percent with metformin-imeglimin. Compared with metformin-placebo, metformin-imeglimin correlated with significant improvements in fasting and the proinsulin/insulin ratio from baseline. The safety profile of the metformin-imeglimin combination was similar to that of metformin-placebo, and the combination was generally well tolerated.

"This phase II study demonstrated that first-in-class imeglimin was well tolerated and effective when combined with metformin as a potential new treatment for ," the authors write.

Several authors disclosed to pharmaceutical companies, including Poxel, which primarily funded the study and manufactures imeglimin.

Explore further: Early intensive diabetes therapy preserves beta-cell function

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Early intensive diabetes therapy preserves beta-cell function

July 6, 2012
(HealthDay) -- Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue ...

Metformin improves blood glucose levels and BMI in very obese children

December 10, 2012
Metformin therapy has a beneficial treatment effect over placebo in improving body mass index (BMI) and fasting glucose levels in obese children, according to a recent study accepted for publication in The Endocrine Society's ...

Lung cancer risk unaffected by metformin use in diabetes

August 30, 2012
(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Metformin may have dual effect in breast cancer

May 9, 2012
(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects are observed according ...

New study examines risks and benefits of the first line treatment for diabetes

April 10, 2012
Although the drug metformin is considered the gold standard in the management of type 2 diabetes, a study by a group of French researchers published in this week's PLoS Medicine suggests that the long-term benefits of this ...

Metformin may lower cancer risk in people with Type 2 diabetes

June 25, 2012
A commonly prescribed diabetes drug, metformin, reduces the overall cancer risk in people with Type 2 diabetes, a large systematic review study finds. The results to be presented at The Endocrine Society's 94th Annual Meeting ...

Recommended for you

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

Immune system killer cells increase risk of diabetes

July 6, 2017
More than half of the German population is obese. One effect of obesity is to chronically activate the immune system, placing it under continuous stress. Researchers in Jens Brüning's team at the Max-Planck-Institute for ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.